Compare PCRX & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCRX | CRMD |
|---|---|---|
| Founded | 2006 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 590.7M |
| IPO Year | 2010 | 2009 |
| Metric | PCRX | CRMD |
|---|---|---|
| Price | $36.33 | $7.39 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 6 |
| Target Price | ★ $33.57 | $15.33 |
| AVG Volume (30 Days) | ★ 1.8M | 825.0K |
| Earning Date | 11-05-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 107.44 | ★ 780.00 |
| EPS | 0.19 | ★ 0.72 |
| Revenue | ★ $541,533,000.00 | $311,709,000.00 |
| Revenue This Year | $3.84 | $8.13 |
| Revenue Next Year | $4.73 | N/A |
| P/E Ratio | $191.32 | ★ $10.36 |
| Revenue Growth | 26.04 | ★ 617.03 |
| 52 Week Low | $18.80 | $6.13 |
| 52 Week High | $36.46 | $13.02 |
| Indicator | PCRX | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 84.38 | 42.42 |
| Support Level | $21.78 | $7.08 |
| Resistance Level | N/A | $9.01 |
| Average True Range (ATR) | 0.59 | 0.22 |
| MACD | 1.38 | -0.00 |
| Stochastic Oscillator | 98.87 | 44.20 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.